About: Early Use of Tocilizumab in Respiratory Failure Associated with Acute COVID -19 Pneumonia in Recipients with Solid Organ Transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early Use of Tocilizumab in Respiratory Failure Associated with Acute COVID -19 Pneumonia in Recipients with Solid Organ Transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Early Use of Tocilizumab in Respiratory Failure Associated with Acute COVID -19 Pneumonia in Recipients with Solid Organ Transplantation
Creator	Antony, Suresh Lance, Jessalyn Sciences, Health Singh, Joya Texas, De Jesus, Mikhail Paso, El
Source	Elsevier; Medline; PMC
abstract	As of May 14, 2020, the World Health Organization has reported approximately 4.3 million cases of the novel Coronavirus Disease (COVID-19) with approximately 294,046 deaths worldwide.(1) Solid organ transplant recipients who are on chronic immunosuppressants fall within a special population of COVID-19 patients since they are more susceptible to complications secondary to COVID-19. Currently, we do not have data on treating COVID-19 patients with solid organ transplants with tocilizumab, an interleukin-6 (IL-6) inhibitor. We report a case of COVID-19 in a patient with a kidney and liver transplant and discuss the early use of tocilizumab to prevent the cytokine storm and attempt to reduce the likelihood of progression to Acute Respiratory Distress Syndrome (ARDS). In addition, we present other COVID-19 related transplant cases reported in the literature outlining the presenting clinical signs and outcomes.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.1016/j.idcr.2020.e00888
bibo:pmid	32685369
has license	no-cc
sha1sum (hex)	ec5ed535a89107973b4612585e77e203694df56a
schema:url	https://doi.org/10.1016/j.idcr.2020.e00888
resource representing a document's title	Early Use of Tocilizumab in Respiratory Failure Associated with Acute COVID -19 Pneumonia in Recipients with Solid Organ Transplantation
has PubMed Central identifier	PMC7318948
has PubMed identifier	32685369
schema:publication	IDCases
resource representing a document's body	covid:ec5ed535a89107973b4612585e77e203694df56a#body_text
is schema:about of	named entity 'COVID -19' named entity 'Respiratory Failure' named entity 'Pneumonia' named entity 'Tocilizumab' named entity 'critically ill' named entity 'cytokine storm' named entity 'prognostic' named entity 'respiratory distress' named entity 'IL-6' named entity 'cytokine' named entity 'COVID' named entity 'myalgia' named entity 'COVID-19' named entity 'liver transplant' named entity 'IL-6' named entity 'mycophenolic acid' named entity 'IL-6R' named entity 'IL-6' named entity 'ICU' named entity 'lung' named entity 'case report' named entity 'COVID' named entity 'case reports' named entity 'pneumothorax' named entity 'kidney' named entity 'cell-mediated immunity' named entity 'intubation' named entity 'solid organ transplants' named entity 'IL-6' named entity 'intubation' named entity 'cefepime' named entity 'immune response' named entity 'PCR' named entity 'Mycophenolic acid' named entity 'intracellular' named entity 'BUN' named entity 'milliliters' named entity 'RAF' named entity 'IL-6 inhibitor' named entity 'case report' named entity 'fever' named entity 'intracellular signal transduction' named entity 'ARDS' named entity 'IL-6 inhibitor' named entity 'IL-6' named entity 'United States' named entity 'signal transduction' named entity 'clinical presentation' named entity 'wheezes' named entity 'transplant recipients' named entity 'protein' named entity 'interleukin-6' named entity 'CDC' named entity 'interleukins' named entity 'Thromboembolic' named entity 'lymphopenia' named entity 'IL-6' named entity 'COVID-19' named entity 'hydroxychloroquine' named entity 'chest tube' named entity 'immunocompetent' named entity 'cytokine storm' named entity 'immunosuppressive' named entity 'lymphocyte' named entity 'Receptor' named entity 'COVID' named entity 'COVID-19' named entity 'cytokine storm' named entity 'physical exam' named entity 'polymerase chain reaction' named entity 'viral load' named entity 'cytokine storm' named entity 'viral load' named entity 'differential diagnoses' named entity 'tocilizumab'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software